

**Independent Auditor's Report on Standalone Financial Results of Hemant Surgical Industries Limited for the half year ended and year ended 31<sup>st</sup> March, 2025 –pursuant to the Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 as amended.**

**To**  
**The Board of Directors,**  
**Hemant Surgical Industries Limited**

**Opinion**

We have audited the accompanying Statement of half yearly and year to date Standalone Financial Results of **Hemant Surgical Industries Limited** ('the Company') for the half Year and for the year ended 31<sup>st</sup> March, 2025 ('the statement'), attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended.

In our opinion and to the best of our information and according to the explanations given to us, the Statement:

- i. is presented in accordance with the requirements of Regulation 33 of the Listing Regulations and
- ii. gives a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Accounting Standards ('AS') and other accounting principles generally accepted in India, of the net profit of the Company for the half year ended and for the year ended 31<sup>st</sup> March 2025.

**Basis for Opinion**

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 ('the Act'). Our responsibilities under those standards are further described in the 'Auditor's Responsibilities for the Audit of the Standalone Financial Result section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ('the ICAI') together with the ethical requirements that are relevant to our audit of the Standalone Financial Statements under the provisions of the Act and the rules there under, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us, is sufficient and appropriate to provide a basis for our opinion.

**Emphasis of Matter**

We draw attention to Note 5 of the standalone financial statements, which describes a fire that occurred at the Company's warehouse dated 25th September, 2024. The fire caused damage to property, plant, and equipment and inventory. As described in the note, management has assessed the impact of the fire and disclosed the financial and operational implications. Our opinion is not modified in respect of this matter.

**Responsibilities of Management and Board of Directors for the Statement**

This Statement, which is the responsibility of the Company's Management and the Board of Director's, has been prepared on the basis of standalone financial statements. The Company's Board of Directors are responsible for the preparation and presentation of the Statement that gives a true and fair view of the net profit and other financial information of the Company in accordance with the accounting principles generally accepted in India, including AS prescribed under Section 133 of the Act, read with relevant rules issued there under and other accounting principles generally accepted in India, and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that gives a true and fair view and is free from material misstatement, whether due to fraud or error.

In preparing the Statement, the Management and Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern, and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

## Auditor's Responsibilities for the Audit of the Statement

Our objectives are to obtain reasonable assurance about whether the Statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with Standards on Auditing, specified under section 143(10) of the Act, will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Statement.

As part of an audit in accordance with the Standards on Auditing, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion on whether the Company has in place adequate internal financial controls with reference to Standalone Financial Statements and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the management and Board of Directors.
- Conclude on the appropriateness of the management's and Board of Director's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represents the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the Listing Regulations, to the extent applicable.

### Other Matters

- i. The statement includes the result for the half year ended 31<sup>st</sup> March, 2025, being the balancing figure between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the half year ended 30<sup>th</sup> September 2024 of the current financial year which were subject to limited review by us.

Our opinion is not modified in respect of these matters.

**For A D V & Associates**  
**Chartered Accountants**  
**FRN: 128045W**

**PRATIK** Digitally signed  
by PRATIK  
KABRA  
**KABRA** Date: 2025.05.28  
18:43:26 +05'30'

**Pratik Kabra**  
**Partner**

**M. No.: 611401**  
**UDIN: 25611401BMHWPE6689**

**Date: 28<sup>th</sup> May 2025**  
**Place: Mumbai**

**HEMANT SURGICAL INDUSTRIES LIMITED**

**ADD : 502,5TH FLOOR, ECSTASY BUSINESS PARK, J.S.D. ROAD, MULUND (W) MUMBAI, 400080**

**CIN :L33110MH1989PLC0511333**

**Website: www.hemantsurgical.com , Email: cs@hemantsurgical.com , Tel No: 022-25915289/022-25912747**

**STANDALONE AUDITED BALANCE SHEET AS AT 31.03.2025**

**(Rs in Lakhs)**

Particulars	As at March 31, 2025 (Audited)	As at March 31, 2024 (Audited)
<b>I Equity &amp; Liabilities</b>		
<b>1.Shareholders funds:</b>		
a.Share Capital	1,044.00	1,044.00
b.Reserves and Surplus	5,255.03	4,441.83
<b>2.Non-Current liabilities:</b>		
a.Long-Term Borrowings	2,333.22	354.22
b.Deffered Tax Liabilities(Net)	-	6.29
b.Long Term Provisions	54.79	38.20
<b>3.Current Liabilities:</b>		
a.Short Term Borrowings	751.11	321.08
b.Trade Payables		
i. Micro enterprises and small enterprises	264.87	186.42
ii. Other than micro enterprises and small enterprises.	3,615.88	2,274.21
c.Other Current Liabilities	1,060.88	1,047.23
d.Short Term Provisions	384.55	290.56
<b>Total</b>	<b>14,764.34</b>	<b>10,004.04</b>
<b>II Assets</b>		
<b>1.Non-Current Assets:</b>		
a. Property, Plant & Equipment and Intangible Assets	3,986.62	1,766.20
b. Capital Work in progress	1,188.15	-
c.Non-Current Investments	145.46	492.82
d.Deferred Tax assets(net)	16.34	-
d.Long Term Loans & Advances	502.62	475.08
e. Other Non Current Assets	124.66	340.32
<b>2.Current Assets:</b>		
a.Current Investments		
b.Inventories	4,247.51	2,105.04
c.Trade Receivables	2,031.15	2,173.66
d.Cash and Cash Equivalents	945.69	1,317.06
e.Short Term Loans and Advances	767.38	1,039.40
f.Other Current Assets	808.76	294.46
<b>Total</b>	<b>14,764.34</b>	<b>10,004.04</b>

For and on behalf of the Board of Directors of  
**HEMANT SURGICAL INDUSTRIES LIMITED**

*Hans Kumar Shamji Shah*

**Hanskumar Shamji Shah**  
Managing Director  
DIN - 00215972  
Place : Mumbai  
Date: 28th May, 2025





**HEMANT SURGICAL INDUSTRIES LIMITED**

**ADD : 502,5TH FLOOR, ECSTASY BUSINESS PARK, J.S.D. ROAD, MULUND (W) MUMBAI, 400080**

**CIN :L33110MH1989PLC0511333**


**Website: www.hemantsurgical.com , Email: cs@hemantsurgical.com , Tel No: 022-25915289/022-25912747**

**STANDALONE AUDITED PROFIT FOR THE HALF YEAR ENDED AS ON 31.03.2025**

**(Rs. In lakhs except EPS)**

Particulars	Half Year Ended			Year Ended	
	31/03/2025	30/09/2024	31/03/2024	31/03/2025	31/03/2024
	(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
<b>I. Revenue from Operations</b>	5765.60	4,887.06	5,809.60	10,652.66	10,560.75
<b>II. Other Incomes</b>	270.40	240.83	167.10	511.24	430.85
<b>III. Total Revenue (a)</b>	<b>6,036.01</b>	<b>5,127.89</b>	<b>5,976.70</b>	<b>11,163.90</b>	<b>10,991.60</b>
<b>IV. Expenses</b>					
1. Cost of Raw Materials Consumed	5,236.36	4,169.19	3,876.12	9,405.56	8,016.24
2. Change in Inventories	(1,123.98)	(729.85)	244.61	(1,853.83)	(265.11)
3. Employee Benefits Expenses	506.63	426.00	405.79	932.62	759.55
4. Finance Costs	143.41	77.02	45.72	220.43	97.15
5. Depreciation	73.90	68.60	52.02	142.49	102.63
6. Other Expenses	591.96	669.13	547.82	1,261.09	1,003.01
<b>V. Total Expenses (b)</b>	<b>5,428.27</b>	<b>4,680.09</b>	<b>5,172.08</b>	<b>10,108.37</b>	<b>9,713.47</b>
<b>V. Profit before Exceptional and Extraordinary Items and Tax</b>	<b>607.73</b>	<b>447.80</b>	<b>804.62</b>	<b>1,055.53</b>	<b>1,278.13</b>
<b>VI. Exceptional Items</b>					
<b>VII. Profit Before Extraordinary items and Tax</b>	<b>607.73</b>	<b>447.80</b>	<b>804.62</b>	<b>1,055.53</b>	<b>1,278.13</b>
<b>VIII. Extraordinary Items</b>					
<b>IX. Profit before tax</b>	<b>607.73</b>	<b>447.80</b>	<b>804.62</b>	<b>1,055.53</b>	<b>1,278.13</b>
<b>X. Tax Expense</b>					
a. Current Tax	164.17	112.70	202.51	276.88	321.68
b. Earliar Year Tax	(11.92)	-	-	(11.92)	-
c. Deffered Tax (Expenses)/Income	39.50	(16.87)	14.40	22.63	(23.54)
<b>XI. Profit for the period from Continuing Operations</b>	<b>494.98</b>	<b>318.23</b>	<b>587.71</b>	<b>813.21</b>	<b>979.99</b>
<b>XII. Profit from Discontinuing Operations</b>	-	-	-	-	-
<b>XIII. Tax Expense of Discontinuing Operations</b>	-	-	-	-	-
<b>XIV. Profit from Discontinuing Operations after Tax</b>	-	-	-	-	-
<b>XV. Profit for the period</b>	<b>494.98</b>	<b>318.23</b>	<b>587.71</b>	<b>813.21</b>	<b>979.99</b>
<b>XVI. Earning per Share (Equated)</b>					
(a) Basic EPS	4.74	3.05	5.70	7.79	9.85
(b) Diluted EPS	4.74	3.05	5.70	7.79	9.85

For and on behalf of the Board of Directors of  
**HEMANT SURGICAL INDUSTRIES LIMITED**

  
**Hanskumar Shamji Shah**  
Managing Director  
DIN - 00215972  
Place : Mumbai  
Date: 28th May, 2025



**HEMANT SURGICAL INDUSTRIES LIMITED**

**ADD : 502,5TH FLOOR, ECSTASY BUSINESS PARK, J.S.D. ROAD, MULUND (W) MUMBAI, 400080**

**CIN :L33110MH1989PLC0511333**

**Website: www.hemantsurgical.com , Email: cs@hemantsurgical.com , Tel No: 022-25915289/022-25912747**

**STANDALONE CASH FLOW STATEMENT FOR THE PERIOD ENDED ON 31 MARCH 2025**

(Rs. In lakhs)

Particulars		For the period ended 31st March, 2025 (Audited)	For the period ended 31st March, 2024 (Audited)
<b>A</b>	<b>CASH FLOW FROM OPERATING ACTIVITIES</b>		
	Net Profit before tax as per Profit And Loss A/c	1055.53	1,278.13
	<b>Adjustments for:</b>		
	Depreciation & Amortisation Expense	142.49	102.63
	Interest Income	(59.23)	(112.09)
	Profit on Sale of Fixed Assets	(17.81)	(1.42)
	Finance Cost	214.89	94.50
	Loss By Fire of Plant and Machinery	116.53	-
		<b>1,452.42</b>	<b>1,361.75</b>
	<b>Operating Profit Before Working Capital Changes</b>		
	Adjusted for (Increase)/ Decrease in:		
	Long term provision	16.59	6.58
	Short term Borrowings	430.03	(84.95)
	Trade Payables	1420.11	41.88
	Other Current Liabilities	13.65	431.16
	Short term provision	21.74	(34.87)
	Inventories	(2,142.47)	(624.37)
	Trade Receivables	142.51	(453.86)
	Loans and Advances	244.49	(566.60)
	Other current assets	(514.30)	(170.52)
		<b>(367.65)</b>	<b>(1,455.55)</b>
	<b>Cash Generated From Operations</b>		
	Appropriation of Profit		
	Net Income Tax paid/ refunded	(192.71)	(321.68)
<b>B</b>	<b>Net Cash Flow from/(used in) Operating Activities: (A)</b>	<b>892.06</b>	<b>(415.48)</b>
	Cash Flow From Investing Activities:		
	Net (Purchases)/Sales of Fixed Assets (including capital work in progress)	(3,768.37)	(567.09)
	Sales of Fixed Assets (including capital work in progress)	235.11	14.91
	Loss By fire of Plant and Machinery	(116.53)	-
	Interest Income	59.23	112.09
	Net Increase/(Decrease) in Non Current Investment	347.36	(456.67)
	Net Increase/(Decrease) in Other Non Current Assets	215.65	(340.32)
		<b>(3,027.55)</b>	<b>(1,237.08)</b>
	<b>Net Cash Flow from/(used in) Investing Activities: (B)</b>		
	Cash Flow from Financing Activities:		
	Net Increase/(Decrease) in Long Term Borrowings	1979.01	48.32
	Proceeds from issue of share	0.00	2,170.16
	Interest on borrowings	(214.89)	(94.50)
<b>C</b>	<b>Net Cash Flow from/(used in) Financing Activities ( C)</b>	<b>1,764.12</b>	<b>2,123.98</b>
	Net Increase/(Decrease) in Cash & Cash Equivalents (A+B+C)	(371.37)	471.41
	Cash & Cash Equivalents As At Beginning of the Year	1317.06	845.65
	Cash & Cash Equivalents As At End of the Year	<b>945.69</b>	<b>1,317.06</b>

For and on behalf of the Board of Directors of

**HEMANT SURGICAL INDUSTRIES LIMITED**

*Hans Kumar*

**Hanskumar Shamji Shah**

Managing Director

DIN - 00215972

Place : Mumbai

Date: 28th May, 2025





**HEMANT SURGICAL INDUSTRIES LIMITED****ADD : 502,5TH FLOOR, ECSTASY BUSINESS PARK, J.S.D. ROAD, MULUND (W) MUMBAI, 400080****CIN :L33110MH1989PLC0511333****NOTES TO STANDALONE AUDITED FINANCIAL RESULTS FOR THE HALF YEAR AND YEAR ENDED 31.03.2025**

1	The above audited standalone financial results of Hemant Surgical Industries Limited ("the Company") for the half year ended March 31, 2025 have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on May 28, 2025.
2	The above audited standalone financial results of the Hemant Surgical Industries Limited for the half year ended March 31, 2025, are prepared in accordance with the recognition and measurement principles laid down in Accounting Standard (AS) 25 - Interim Financial Reporting, prescribed under section 133 of the Companies Act, 2013 and other recognised accounting principles generally accepted in India.
3	As per MCA Notification dated 16th February, 2015 Companies whose shares are listed on SME exchange as referred to in Chapter XB of SEBI (Issue of Capital and Disclosure Requirements) Regulation, 2009, are exempted from the compulsory requirement of adoption of IND-AS.
4	In terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, the audited standalone financial results for the half year ended March 31, 2025 has been reviewed by Statutory Auditors of the Company.
5	On 25th September, 2024, the company experienced a fire incident at its manufacturing unit located in Sonale, which resulted in damage in Solar Panel, AHU (Air Handling Units) and inventory. The loss in Solar Panel, AHU (Air Handling Units) is 116.53 Lakhs which is recognised in other expenses in financial statements as these assets were not covered under insurance. The loss in inventories is Rs 387.87 Lakhs which is partially covered under insurance. The company has received insurance claim of Rs 193.10 Lakhs for loss of inventories which is recognised in Other income in Financial Statement. No separate line item has been presented in the profit and loss account for loss of inventories, as the impact has been incorporated in the inventory valuation.
6	The Company is operating in a Single Segment. Hence, the above financial results are based on single segment only.
7	Earning Per share: Earning Per share is calculated on the weighted average of the share capital received by the company. Half yearly EPS is not annualised.
8	Figures of half year ended on March 31, 2025 represent the difference between the audited figures in respect of full financial years and the published unaudited figures of six months ended on September 30, 2024.
9	The figures of the previous period have been re-grouped or rearranged, wherever considered necessary.
10	The Proceeds of IPO have been utilised till March 31, 2025 as per the below mentioned table:

(Amount in Lakhs)

Object of the Issue	Amount Allocated for the Object	Amount Utilised	Balance Available in Bank	Balance Available as Fixed Deposits
Public Issue Expenses	313.88	313.88	-	-
To meet Working Capital Requirement	1,000.00	1,000.00	-	-
Funding Capital Expenditure towards installation of additional plant and	751.26	688.42	38.00	24.84
General Corporate Purpose	418.86	418.86	-	-
<b>Total</b>	<b>2,484.00</b>	<b>2,421.16</b>	<b>38.00</b>	<b>24.84</b>

For and on behalf of the Board of Directors of

**HEMANT SURGICAL INDUSTRIES LIMITED**

  
**Hanskumar Shamji Shah**  
Managing Director  
DIN - 00215972  
Place: Mumbai  
Date: 28th May, 2025



**Independent Auditor's Report on Consolidated Financial Results of HEMANT SURGICAL INDUSTRIES LIMITED for the half year ended and year ended 31<sup>st</sup> March, 2025 pursuant to the Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, as amended.**

**To**  
**The Board of Directors,**  
**HEMANT SURGICAL INDUSTRIES LIMITED**

**Opinion**

We have audited the accompanying Statement of Consolidated Financial Results for the Half year ended 31<sup>st</sup> March, 2025 and for the Year ended 31<sup>st</sup> March, 2025 of **HEMANT SURGICAL INDUSTRIES LIMITED** ('the Parent') which includes its share in the profits of its company **SOLAR OPTO-MEDIC PRIVATE LIMITED** (the Parent and its Wholly owned Subsidiary together referred as "the Group") ('the statement'), attached herewith, being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('the Listing Regulations')..

In our opinion and to the best of our information and according to the explanations given to us, the Statement:

- i. includes the financial results of the following entities:  
**I. SOLAR OPTO-MEDIC PRIVATE LIMITED**
- ii. is presented in accordance with the requirements of Regulation 33 of the Listing Regulations; and;
- iii. gives a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Accounting Standards ('AS') and other accounting principles generally accepted in India, of the net profit and other financial information of the Group for the half year ended 31<sup>st</sup> March, 2025 and for the year ended 31<sup>st</sup> March 2025.

**Basis for Opinion**

We conducted our audit in accordance with the Standards on Auditing (SAs') specified under section 143(10) of the Companies Act, 2013 ('the Act'). Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Consolidated Financial Result section of our report. We are independent of the Group in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ('the ICAI') together with the ethical requirements that are relevant to our audit of the Consolidated Financial Statements for the year ended under the provisions of the Act and the rules there under, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us, is sufficient and appropriate to provide a basis for our opinion.

**Emphasis of Matter**

We draw attention to Note 5 of the Consolidated financial statements, which describes a fire that occurred at the Company's warehouse dated 25<sup>th</sup> September, 2024. The fire caused damage to property, plant, and equipment and inventory. As described in the note, management has assessed the impact of the fire and disclosed the financial and operational implications. Our opinion is not modified in respect of this matter.

**Responsibilities of Management and Board Of Directors for the Statement**

This Statement, which is the responsibility of the Parent Company's Management, has been prepared on the basis of the audited consolidated financial statements. This Statement, which is the responsibility of the Parent Company's Management and approved by the Board of Directors, has been prepared on the basis of the audited consolidated financial statements. This responsibility includes the preparation and presentation of the Statement that give a true and fair view of the consolidated net profit and other financial information of the Group in accordance with the recognition and measurement principles laid down in the Accounting Standards, prescribed under Section 133 of the Act, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulations 33 of the Listing Regulations.

The respective Management and Board of Directors of the companies included in the Group are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Group and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the respective financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the Statement by the Management and the Directors of the Parent, as aforesaid.

In preparing the Statement, the respective Management and Board of Directors of the companies included in the Group are responsible for assessing the ability of the respective entities to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate their respective entities or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group are also responsible for overseeing the Company's financial reporting process.

### **Auditor's Responsibilities for the Audit of the Statement**

Our objectives are to obtain reasonable assurance about whether the Statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with Standards on Auditing, specified under section 143(10) of the Act, will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Statement.

As part of an audit in accordance with the Standards on Auditing, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion on whether the Company has in place adequate internal financial controls with reference to Consolidated Financial Statements and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the management.
- Conclude on the appropriateness of the management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represents the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the standalone/consolidated financial statements/financial results/financial information of the entities within the Group to express an opinion on the Statement. We are responsible for the direction, supervision and performance of the audit of financial information of such entities included in the Statement of which we are the independent auditors. For the other entities included in the Statement, which have been audited by the other auditors, such other auditors remain



responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.

We communicate with those charged with governance of the Parent and such other entities included in the Statement of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the Listing Regulations, to the extent applicable.

#### **Other Matters**

- i. The consolidated financial statements for the year ended 31st March 2025 are the first such financial statements prepared by the Holding Company, pursuant to the requirements of AS 21 "Consolidated Financial Statements".
- ii. We did not audit the financial statements/financial information of Solar Opto Medic Private Limited which is wholly owned Subsidiary whose financial statements include total assets of RS 90.45 Lakhs and net assets of Rs 38.53 Lakhs as at March 31,2025 and revenue of RS 11.89 Lakhs for the year ended on the date. This Financial statements/financial information have been audited by other auditors whose report has been furnished to us by the management and our opinion on consolidated financial statements, is so far relates to the amounts and disclosures included in respect of these subsidiaries, jointly controlled entities and associates, is based solely on the reports of the other auditor.
- iii. The statement includes the result for the half year ended 31<sup>st</sup> March, 2025, being the balancing figure between the consolidated audited figures in respect of the full financial year and the published standalone unaudited year to date figures up to the half year ended 30<sup>th</sup> September 2024 of the current financial year which were subject to limited review by us.

Our opinion is not modified in respect of these matters.

**For A D V & Associates**

**Chartered Accountants**

**FRN: 128045W**

**PRATIK** Digitally signed  
by PRATIK KABRA  
Date: 2025.05.28  
18:43:58 +05'30'  
**KABRA**

**Pratik Kabra**

**Partner**

**M. No.: 611401**

**UDIN: 25611401BMHWPF5453**

**Date: 28<sup>th</sup> May 2025**

**Place: Mumbai**

**HEMANT SURGICAL INDUSTRIES LIMITED**

ADD : 502,5TH FLOOR, ECSTASY BUSINESS PARK, J.S.D. ROAD, MULUND (W) MUMBAI, 400080

CIN : L33110MH1989PLC0511333

Website: www.hemantsurgical.com , Email: es@hemantsurgical.com , Tel No: 022-25915289/022-25912747

**CONSOLIDATED AUDITED PROFIT FOR THE HALF YEAR ENDED AS ON 31.03.2025**

(Rs. In lakhs except EPS)

Particulars	Half Year Ended			Year Ended	
	31/03/2025	30/09/2024	31/03/2024	31/03/2025	31/03/2024
	(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
I. Revenue from Operations	5776.63			10,663.69	-
II. Other Incomes	271.20			512.03	-
<b>III. Total Revenue (a)</b>	<b>6,047.83</b>			<b>11,175.73</b>	<b>-</b>
<b>IV. Expenses</b>					
1. Cost of Raw Materials Consumed	5,256.51			9,425.71	-
2. Change in Inventories	(1,125.44)			(1,855.29)	-
3. Employee Benefits Expenses	507.62			933.61	-
4. Finance Costs	143.39			220.41	-
5. Depreciation	73.96			142.56	-
6. Other Expenses	593.01			1,262.14	-
<b>V. Total Expenses (b)</b>	<b>5,449.04</b>			<b>10,129.14</b>	<b>-</b>
<b>VI. Profit before Exceptional and Extraordinary Items and Tax</b>	<b>598.79</b>			<b>1,046.59</b>	<b>-</b>
VII. Exceptional Items				-	-
<b>VII. Profit Before Extraordinary items and Tax</b>	<b>598.79</b>			<b>1,046.59</b>	<b>-</b>
VIII. Extraordinary Items				-	-
<b>IX. Profit before tax</b>	<b>598.79</b>			<b>1,046.59</b>	<b>-</b>
<b>X. Tax Expense</b>					
a. Current Tax	164.17			276.88	-
b. Earlier Year Tax	(11.92)			(11.92)	-
c. Deferred Tax (Expenses)/Income	39.33			22.47	-
<b>XI. Profit for the period from Continuing Operations</b>	<b>485.87</b>			<b>804.10</b>	<b>-</b>
XII. Profit from Discontinuing Operations	-			-	-
XIII. Tax Expense of Discontinuing Operations	-			-	-
XIV. Profit from Discontinuing Operations after Tax	-			-	-
<b>XV. Profit for the period</b>	<b>485.87</b>			<b>804.10</b>	<b>-</b>
<b>XVI. Earning per Share (Equated)</b>					
(a) Basic EPS	4.65			7.70	-
(b) Diluted EPS	4.65			7.70	-

For and on behalf of the Board of Directors of  
**HEMANT SURGICAL INDUSTRIES LIMITED**

*Hans Kumar*  
**Hanskumar Shamji Shah**  
Managing Director  
DIN - 00215972  
Place : Mumbai  
Date: 28th May, 2025



**HEMANT SURGICAL INDUSTRIES LIMITED**

**ADD : 502,5TH FLOOR, ECSTASY BUSINESS PARK, J.S.D. ROAD, MULUND (W) MUMBAI, 400080**

**CIN :L33110MH1989PLC0511333**

**Website: www.hemantsurgical.com , Email: cs@hemantsurgical.com , Tel No: 022-25915289/022-25912747**

**CONSOLIDATED AUDITED BALANCE SHEET AS AT 31.03.2025**

**(Rs in Lakhs)**

Particulars	As at March 31, 2025 (Audited)	As at March 31, 2024 (Audited)
<b>I Equity &amp; Liabilities</b>		
<b>1.Shareholders funds:</b>		
a.Share Capital	1,044.00	-
b.Reserves and Surplus	5,273.31	-
<b>2.Non-Current liabilities:</b>		
a.Long-Term Borrowings	2,333.22	-
b.Deferred Tax Liabilities(Net)	-	-
b.Long Term Provisions	54.79	-
<b>3.Current Liabilities:</b>		
a.Short Term Borrowings	769.77	-
b.Trade Payables		-
i. Micro enterprises and small enterprises	264.87	-
ii. Other than micro enterprises and small enterprises.	3,633.42	-
c.Other Current Liabilities	1,072.94	-
d.Short Term Provisions	384.55	-
<b>Total</b>	<b>14,830.88</b>	<b>-</b>
<b>II Assets</b>		
<b>1.Non-Current Assets:</b>		
a. Property, Plant & Equipment and Intangible Assets	3,992.86	-
b. Capital Work in progress	1,188.15	-
c.Non-Current Investments	125.21	-
d.Deferred Tax assets(net)	16.34	-
d.Long Term Loans & Advances	504.13	-
e. Other Non Current Assets	124.66	-
<b>2.Current Assets:</b>		
a.Current Investments		-
b.Inventories	4,313.63	-
c.Trade Receivables	2,038.22	-
d.Cash and Cash Equivalents	954.69	-
e.Short Term Loans and Advances	763.72	-
f.Other Current Assets	809.26	-
<b>Total</b>	<b>14,830.88</b>	<b>-</b>

For and on behalf of the Board of Directors of  
**HEMANT SURGICAL INDUSTRIES LIMITED**

*Hans Kumar*

**Hanskumar Shamji Shah**  
Managing Director  
DIN - 00215972  
Place : Mumbai  
Date: 28th May, 2025





**HEMANT SURGICAL INDUSTRIES LIMITED**

**ADD : 502,5TH FLOOR, ECSTASY BUSINESS PARK, J.S.D. ROAD, MULUND (W) MUMBAI, 400080**

**CIN : L33110MH1989PLC0511333**

**Website: www.hemantsurgical.com , Email: cs@hemantsurgical.com , Tel No: 022-25915289/022-25912747**

**CONSOLIDATED CASH FLOW STATEMENT FOR THE PERIOD ENDED ON 31 MARCH 2025**

(Rs. In lakhs)

Particulars		For the period ended 31st March, 2025 (Audited)	For the period ended 31st March, 2024 (Audited)
<b>A</b>	<b>CASH FLOW FROM OPERATING ACTIVITIES</b>		
	Net Profit before tax as per Profit And Loss A/c	1046.59	-
	<b>Adjustments for:</b>		
	Depreciation & Amortisation Expense	142.56	-
	Interest Income	(59.16)	-
	Profit on Sale of Fixed Assets	(17.81)	-
	Finance Cost	214.87	-
	Loss By Fire of Plant and Machinery	116.53	-
		<b>1,443.59</b>	<b>-</b>
	<b>Operating Profit Before Working Capital Changes</b>		
	Adjusted for (Increase)/ Decrease in:		
	Long term provision	16.59	-
	Short term Borrowings	420.94	-
	Trade Payables	1436.22	-
	Other Current Liabilities	18.29	-
	Short term provision	11.65	-
	Inventories	(2,143.93)	-
	Trade Receivables	139.56	-
	Loans and Advances	248.14	-
	Other current assets	(514.30)	-
		<b>(366.84)</b>	<b>-</b>
	<b>Cash Generated From Operations</b>		
	Appropriation of Profit		
	Net Income Tax paid/ refunded	(192.71)	-
	<b>Net Cash Flow from/(used in) Operating Activities: (A)</b>	<b>884.04</b>	<b>-</b>
<b>B</b>	<b>Cash Flow From Investing Activities:</b>		
	Net (Purchases)/Sales of Fixed Assets (including capital work in progress)	(3,757.34)	-
	Sales of Fixed Assets (including capital work in progress)	224.08	-
	Loss By fire of Plant and Machinery	(116.53)	-
	Interest Income	59.16	-
	Net Increase/(Decrease) in Non Current Investment	347.36	-
	Net Increase/(Decrease) in Other Non Current Assets	215.65	-
	<b>Net Cash Flow from/(used in) Investing Activities: (B)</b>	<b>(3,027.61)</b>	<b>-</b>
	<b>Cash Flow from Financing Activities:</b>		
	Net Increase/(Decrease) in Long Term Borrowings	1979.01	-
	Proceeds from issue of share	0.00	-
	Interest on borrowings	(214.87)	-
	<b>Net Cash Flow from/(used in) Financing Activities (C)</b>	<b>1,764.14</b>	<b>-</b>
<b>C</b>	<b>Net Increase/(Decrease) in Cash &amp; Cash Equivalents (A+B+C)</b>	<b>(379.44)</b>	<b>-</b>
	Cash & Cash Equivalents As At Beginning of the Year	1334.13	-
	Cash & Cash Equivalents As At End of the Year	<b>954.69</b>	<b>-</b>

Note: For the Purpose of Preparing Cash flow statement, the closing balance of previous year of the holding company and opening balance its subsidiary company in the date of acquisition have been considered as comparative figures.

For and on behalf of the Board of Directors of

**HEMANT SURGICAL INDUSTRIES LIMITED**

*Hans Kumar*

**Hans Kumar Shamji Shah**

Managing Director

DIN - 00215972

Place : Mumbai

Date: 28th May, 2025



**HEMANT SURGICAL INDUSTRIES LIMITED****ADD : 502,5TH FLOOR, ECSTASY BUSINESS PARK, J.S.D. ROAD, MULUND (W) MUMBAI, 400080****CIN : L33110MH1989PLC0511333****NOTES TO CONSOLIDATED AUDITED FINANCIAL RESULTS FOR THE HALF YEAR AND YEAR ENDED 31.03.2025**

1	The above audited consolidated financial results of Hemant Surgical Industries Limited ("the Holding") and profit from its share in wholly owned subsidiary for the half year ended March 31, 2025 have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on May 28th, 2025.
2	The above audited consolidated financial results of the Hemant Surgical Industries Limited for the half year ended March 31, 2025, are prepared in accordance with the recognition and measurement principles laid down in Accounting Standard (AS) 25 - Interim Financial Reporting, prescribed under section 133 of the Companies Act, 2013 and other recognized accounting principles generally accepted in India.
3	As per MCA Notification dated 16th February, 2015 Companies whose shares are listed on SME exchange as referred to in Chapter XB of SEBI (Issue of Capital and Disclosure Requirements) Regulation, 2009, are exempted from the compulsory requirement of adoption of IND-AS.
4	In terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, the consolidated audited financial results for the half year ended March 31, 2025 has been reviewed by Statutory Auditors of the Company.
5	On 25th September, 2024, the company experienced a fire incident at its manufacturing unit located in Sonale, which resulted in damage in Solar Panel, AHU (Air Handling Units) and inventory. The loss in Solar Panel, AHU (Air Handling Units) is 116.53 Lakhs which is recognized in other expenses in financial statements as there assets were not covered under insurance. The loss in inventories is Rs 387.87 Lakhs which is partially covered under insurance. The company has received insurance claim of Rs 193.10 Lakhs for loss of inventories which is recognized in Other income in Financial Statement. No separate line item has been presented in the profit and loss account for loss of inventories, as the impact has been incorporated in the inventory valuation.
6	The Company acquired control over its Subsidiary company on 13 March 2025. Accordingly, the financial results of its subsidiary company have been consolidated from the date of acquisition in these financial statements, in accordance with Accounting Standard 21. As the acquisition occurred during the current financial year, the consolidated financial statements do not include the financial results of the subsidiary for the prior period. Accordingly, comparative figures for the consolidated financial results have not been presented.
7	The Company is operating in a Single Segment. Hence, the above financial results are based on single segment only.
8	Earning Per share: Earning Per share is calculated on the weighted average of the share capital received by the company. Half yearly EPS is not annualized.
9	Figures of half year ended on March 31, 2025 represent the difference between the consolidated audited figures in respect of full financial years and the published standalone unaudited figures of six months ended on September 30, 2024.
10	The figures of the previous period have been re-grouped or rearranged, wherever considered necessary.
11	The Proceeds of IPO have been utilized till March 31, 2025 as per the below mentioned table:

(Amount in Lakhs)

Object of the Issue	Amount Allocated for the Object	Amount Utilized	Balance Available in Bank	Balance Available as Fixed Deposits
Public Issue Expenses	313.88	313.88	-	-
To meet Working Capital Requirement	1,000.00	1,000.00	-	-
Funding Capital Expenditure towards installation of additional plant and	751.26	688.42	38.00	24.84
General Corporate Purpose	418.86	418.86	-	-
<b>Total</b>	<b>2,484.00</b>	<b>2,421.16</b>	<b>38.00</b>	<b>24.84</b>

For and on behalf of the Board of Directors of  
**HEMANT SURGICAL INDUSTRIES LIMITED**

  
**Hanskumar Shamji Shah**  
 Managing Director  
 DIN - 00215972  
 Place: Mumbai  
 Date: 28th May, 2025



May 28, 2025

To BSE Limited (SME)  
The Department of Corporate Services  
P.J. Towers, Dalal Street,  
Mumbai 400 001

Dear Sir/Madam,

**Scrip code: 543916**

**Sub.: Declaration pursuant to Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) (Amendment) Regulations, 2016**

Dear Sir/Madam,

I, Kaushik Hanskumar Shah, Chief Financial Officer of Hemant Surgical Industries Limited having its registered office at 502, Ecstasy Business Park, Co-op Society Limited, 5<sup>th</sup> Floor, J.S.D. Road, Mulund (West), Mumbai, Maharashtra, 400080, India, hereby declare that A D V & Associates, Chartered Accountants (FRN-128045W), Statutory Auditors of our Company, have issued an Audit Report with unmodified opinion on the audited financial results of the Company (Standalone & Consolidated) for the half year and year ended on March 31, 2025.

This declaration is given in compliance to Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Kindly take the above report on record and acknowledge.

Thanking you,

Yours faithfully,

**For Hemant Surgical Industries Limited**



**Kaushik Hanskumar Shah**  
Chief Financial Officer

